Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15030736 | 0.83 | TP53 (0.33) | CHRM1KHK | |
| SCHEMBL19981427 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL25775999 | 0.75 | — | — | |
| SCHEMBL19981530 | 0.73 | SMN1; SMN2 (0.38) | CHRM2CHRM1CHRM3L3MBTL3L3MBTL1 | |
| SCHEMBL3159987 | 0.73 | HTR6 (0.41) | KHKL3MBTL3L3MBTL1 | |
| SCHEMBL2554838 | 0.71 | KMT2A (0.44) | KHKL3MBTL3L3MBTL1 | |
| SCHEMBL29904663 | 0.71 | KHK (0.36) | CHRM2CHRM1CHRM3KHKL3MBTL3 | |
| SCHEMBL408996 | 0.70 | — | — | |
| SCHEMBL15443901 | 0.70 | CHRM1 (0.35) | CHRM1KHK | |
| Hydrochloric Acid SCHEMBL26135888 | 0.69 | KMT2A (0.47) | KHKL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788487-B1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2788488-B1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |